Lev Moonens

Lev Moonens
Name	Lev Moonens
Birth date	1979
Birth place	Brussels
Fields	Immunology; Oncology; Molecular Biology
Workplaces	Université libre de Bruxelles; VIB; Stanford University; Institut Pasteur
Alma mater	Université libre de Bruxelles; Harvard University; University of Cambridge
Known for	Checkpoint inhibitor research; T-cell modulation; PD-1/PD-L1 pathway studies
Awards	European Research Council grant; Lasker Award (nominee)

Lev Moonens is a Belgian immunologist and translational scientist noted for mechanistic studies of T cell regulation and the molecular basis of immune checkpoint pathways. His work spans basic biochemical characterization, structural biology, and clinical translation in oncology and infectious disease. Moonens has held positions at major research institutions and collaborated with leading laboratories across Europe and North America.

Early life and education

Moonens was born in Brussels and raised in a family with members working at the Royal Belgian Institute of Natural Sciences and the University of Ghent. He completed undergraduate studies at the Université libre de Bruxelles with a degree in molecular biology, followed by doctoral research at Harvard University focusing on receptor–ligand interactions in adaptive immunity under advisors connected to the National Institutes of Health and Massachusetts General Hospital. Postdoctoral training included structural biology and cryo-electron microscopy at the University of Cambridge and a fellowship at Stanford University where he worked alongside investigators affiliated with the Howard Hughes Medical Institute and the Dana–Farber Cancer Institute.

Academic and research career

Moonens began his independent career at the VIB and later joined the faculty of the Université libre de Bruxelles while maintaining collaborative labs at the Institut Pasteur and partnerships with the European Molecular Biology Laboratory. His laboratory combined techniques from structural biology, protein engineering, and cellular immunology, leveraging resources from facilities such as the European Synchrotron Radiation Facility and the European Bioinformatics Institute. He led multidisciplinary teams integrating expertise from investigators previously associated with the Max Planck Society, Cold Spring Harbor Laboratory, and the Francis Crick Institute. Moonens served on grant review panels for the European Research Council and advisory boards for translational programs at the National Cancer Institute and the Wellcome Trust.

Contributions to immunology and checkpoint inhibitor research

Moonens’s research advanced understanding of checkpoint receptor–ligand geometry, affinity modulation, and signaling consequences. He characterized structural interfaces between receptors such as PD-1 and PD-L1, delineating contact residues and conformational changes using X-ray crystallography and cryo-EM—techniques developed at institutions including the Rutherford Appleton Laboratory and the Max Planck Institute for Biophysical Chemistry. His group identified regulatory motifs influencing interactions involving receptors that include CTLA-4, TIM-3, and LAG-3, mapping similarities and divergences from canonical immune synapse components described by teams at University of Oxford and Yale University. By integrating data from labs at the Broad Institute and the Sanger Institute, Moonens proposed models for differential checkpoint blockade outcomes observed in clinical trials run by consortia including Memorial Sloan Kettering Cancer Center and Gustave Roussy. He collaborated with biotech partners such as Genentech, Bristol Myers Squibb, and Roche to translate mechanistic insights into engineered antibody formats and bispecific constructs tested in preclinical models developed at Amsterdam UMC and Karolinska Institutet.

Moonens also investigated checkpoint pathways in chronic infection contexts, drawing on comparative studies with findings from the Walter Reed Army Institute of Research and the Centers for Disease Control and Prevention. His team evaluated biomarkers predictive of response to checkpoint blockade, working with datasets generated by the Cancer Genome Atlas consortium and clinical networks at Johns Hopkins Hospital and University College London Hospital.

Awards and honors

Moonens received a competitive European Research Council grant for his molecular immunology program and was a finalist for the Lasker Award in a collaborative nomination highlighting checkpoint biology. He was granted investigator awards from foundations associated with the Bill & Melinda Gates Foundation and the Cancer Research Institute, and was elected to societies including the European Academy of Sciences and the Royal Academy of Belgium. Moonens has held visiting scholar appointments at the Karolinska Institutet and delivered invited lectures at conferences organized by American Association for Cancer Research, European Society for Medical Oncology, and the Cold Spring Harbor Laboratory meetings.

Selected publications

- Moonens L., et al. Structural basis for PD-1/PD-L1 interaction and blockade. Journal article co-authored with teams from Stanford University, Harvard Medical School, and University of Cambridge; cited in reviews by New England Journal of Medicine and Nature Reviews Immunology. - Moonens L., et al. Engineering bispecific checkpoint modulators to enhance anti-tumor immunity. Collaborative study with Genentech and Memorial Sloan Kettering Cancer Center; published alongside datasets deposited with the European Nucleotide Archive. - Moonens L., et al. Comparative analysis of TIM-3 and LAG-3 signaling in chronic infection. Multi-institutional work involving Institut Pasteur, Johns Hopkins University, and Karolinska Institutet; referenced by policy briefs at the World Health Organization.

Personal life and legacy

Moonens has been active in mentorship programs linked to the European Molecular Biology Organization and outreach initiatives coordinated with the Belgian Ministry of Science and the Royal Institute for Cultural Heritage. Colleagues from institutions such as VIB, Institut Pasteur, and Stanford University credit him with shaping translational pipelines that bridged academic discovery and industrial development at companies including Bristol Myers Squibb and Roche. His legacy includes trainees who subsequently joined faculties at University of Oxford, University of California, San Francisco, and Weill Cornell Medicine and contributed to checkpoint inhibitor trials at centers like Gustave Roussy and Memorial Sloan Kettering Cancer Center.

Category:Belgian scientists Category:Immunologists